New Delhi:
A vaccine being developed by Pune-based Gennova has become India’s first household mRNA candidate to gain permission for a human clinical trial, the government said today. MRNA vaccines do not use the conventional model to produce an immune response.
“The mRNA vaccine carries the molecular instructions to make the protein in the body through a synthetic RNA from the virus,” a government statement read.
MRNA vaccines are considered safe because they are “non-infectious, non-integrative in nature, and degraded by standard cellular mechanisms.”
Vaccines developed by the US companies Pfizer and Moderna, which are said to be more than 90 percent effective, use the mRNA model.
AstraZeneca-Oxford’s Covishield vaccine, which has been shown to be 70 percent effective and is being manufactured by the Serum Institute of India, uses the 50-year-old ‘adenovirus vector-based antigen’ platform.
The company has developed the candidate vaccine in collaboration with HDT Biotech Corporation, a US company.
“HGCO19 (the code name for the vaccine) has already demonstrated safety, immunogenicity, neutralizing antibody activity in animals. The neutralizing antibody response of the vaccine in mice and non-human primates was comparable to sera from COVID convalescent patients. -19, “the statement read.
While mRNA vaccines developed by US companies require a subzero temperature to remain stable, “HGCO19” remains stable at 2-8 degrees Celsius for two months, the Center said.
If approved, the new vaccine could prove more effective in Indian conditions, as it remains stable at normal refrigerator temperatures and eliminates the need to develop cold storage infrastructure in remote parts of the country.
.
